Semaglutide Shortage Ending: Dates, Refill Rules, and Next Steps

9 min read

Share

A cream felt calendar.

TL;DR

The FDA declared the shortage of semaglutide injection products resolved on February 21, 2025. For anyone following news about the semaglutide shortage ending, that decision changed the rules for routine compounded copies after temporary enforcement periods. It did not guarantee local stock, insurance coverage, or lower prices. We recommend confirming the product, dose, concentration, and next injection date with the pharmacy and prescriber before making a change.

Is the semaglutide shortage ending? The short answer

Is the semaglutide shortage ending? The short answer

Under the FDA’s national shortage process, the semaglutide injection shortage has ended. The agency declared it resolved on February 21, 2025.

That finding addressed national supply and demand. It did not promise that Wegovy, Ozempic, or every dose would be available at each pharmacy.

Four separate issues still affect access:

  • FDA shortage status
  • Local pharmacy inventory
  • Insurance coverage and cash price
  • Prescription and dispensing requirements

The FDA also provided temporary enforcement periods for affected compounders. Those periods ended on different dates based on the type of facility.

What the February 21, 2025 FDA decision changed

The decision removed the shortage-based justification that had allowed broader compounding of products considered copies of approved semaglutide drugs.

Approved products remained subject to prescription requirements, pharmacy inventory, distribution limits, and insurance review. The FDA did not require every pharmacy to stock every strength.

What the decision did not change

The decision did not:

  • Guarantee nearby inventory
  • Reduce the cash price
  • Approve compounded semaglutide products
  • Create an individual switching plan
  • Establish a universal dose conversion

Another strength being available does not make it an appropriate substitute. We recommend getting new instructions from the prescriber before changing the product, dose, or schedule.

The 2025 compounded semaglutide deadline timeline

Three dates shaped the transition away from broad shortage-based compounding:

DateFDA actionPractical effect
February 21, 2025Declared the semaglutide injection shortage resolvedStarted the transition away from shortage-based compounding
April 22, 2025End of the stated enforcement-discretion period for affected Section 503A compoundersSome state-licensed pharmacies stopped routine compounded refills
May 22, 2025End of the stated period for affected Section 503B outsourcing facilitiesSome facilities stopped making or supplying routine copies

Enforcement discretion was temporary. It did not amount to FDA approval of a compounded product or confirmation that every formula complied with federal and state law.

February 21, 2025: FDA resolves the shortage

This was the national shortage decision, not necessarily a patient’s final refill date. Pharmacies still had to review their facility type, prescriptions, ingredient sources, state rules, and FDA policy.

April 22, 2025: the stated 503A window ends

The FDA’s stated enforcement period for affected Section 503A compounders ended on April 22, 2025. A 503A pharmacy generally compounds medication for an identified patient based on a prescription.

An available refill shown in an app does not guarantee that the pharmacy can still dispense it.

May 22, 2025: the stated 503B window ends

The corresponding period for affected Section 503B outsourcing facilities ended on May 22, 2025.

This was not a vial’s beyond-use date or a universal last-order date. Individual facilities could change their policies based on their operations and interpretation of current requirements.

Why your pharmacy may still have no semaglutide

Why your pharmacy may still have no semaglutide

The FDA assesses national conditions. Pharmacies manage local demand, wholesaler shipments, inventory costs, and stock for individual strengths.

A local gap may result from:

  • High demand for one strength
  • Wholesaler or shipment limits
  • Delayed deliveries
  • A pharmacy’s stocking policy
  • Insurance or prior authorization issues
  • A prescription that needs clarification

Ask about the exact brand, strength, and dosage form. Our GLP-1 medication list by active ingredient can help distinguish products, but the prescriber must select the treatment.

National supply does not equal local stock

One pharmacy may lack the prescribed Wegovy strength while another has it. The first location may also stock different strengths.

That local shortage does not reverse the FDA’s national finding. It also does not make another dose or product interchangeable without prescriber approval.

Questions to ask the pharmacy

We suggest asking:

  • Is the problem inventory, payment, prior authorization, or the prescription?
  • Is the exact product and strength unavailable?
  • Can nearby locations check their stock?
  • Does the pharmacy expect another shipment?
  • Is its compounding policy affecting the refill?
  • Does a transfer require action from the patient or prescriber?

Confirm the pharmacy’s process rather than assuming it can reserve stock or transfer the prescription.

What the shortage ending means for compounded semaglutide

The shortage resolution closed the broad route for making routine copies based on limited commercial availability. It did not create a simple blanket ban covering every patient-specific compounded prescription.

Whether compounding remains permissible depends on the facility, prescription, formula, clinical circumstances, and current federal and state requirements. Marketing a product as “custom” or “personalized” does not settle that question.

What “essentially a copy” means

In general, compounders face restrictions on routinely replacing a commercially available drug with the same or a closely similar product.

Section 503A pharmacies and Section 503B outsourcing facilities operate under different rules. Neither designation means every product is FDA-approved, lawful in every circumstance, or clinically suitable.

The narrow patient-specific path

In some circumstances, a prescriber may determine that a compounded variation produces a significant clinical difference for an identified patient.

The prescriber should document the specific clinical reason. Price, preference, or a general claim of personalization may not establish that need, and documentation does not override other legal requirements.

Why an added vitamin or custom dose may not be enough

Adding vitamin B12, changing the concentration, or making a small dose adjustment does not automatically avoid restrictions on copies.

The prescriber and compounder must support the patient-specific rationale and meet all other applicable standards.

How to check a compounding pharmacy and its semaglutide

A 503A pharmacy generally fills patient-specific prescriptions under state licensure and applicable federal conditions. A 503B outsourcing facility registers with the FDA and is subject to additional federal requirements.

Registration is not FDA approval of each product. Before paying, use our guide to verify an online pharmacy and its credentials.

Semaglutide base, sodium, and acetate are not the same label

FDA-approved semaglutide products use semaglutide base. Semaglutide sodium and semaglutide acetate are salt forms and should not be treated as identical labels.

Check the prescription and vial rather than relying on a clinic’s website or advertising.

Five records to verify

We recommend checking:

  1. State pharmacy license and disciplinary history
  2. FDA registration if the facility claims 503B status
  3. Dispensing pharmacy name and address
  4. Active ingredient and concentration
  5. Lot number, storage instructions, and beyond-use date

Keep the packaging, vial, receipt, and dosing instructions. Our pharmacy guides can also help compare pharmacy procedures and costs.

What to do before your next semaglutide refill

A denied refill calls for clear information, not stockpiling or an unapproved schedule change. When possible, contact the prescriber before the current supply runs out.

Record these six facts

Write down:

  1. Date and amount of the last injection
  2. Exact product, concentration, and dose
  3. Doses remaining and the beyond-use date
  4. Date of the next planned injection
  5. Prescription status and refills remaining
  6. Prescriber’s name and secure contact method

Do not split, combine, stretch, or stockpile doses without clinical instructions.

Ask the pharmacy for a clear reason

Find out whether the refill is blocked by inventory, prescription status, sourcing, pharmacy policy, payment, or prior authorization. If compounded medication is involved, ask whether the pharmacy is a 503A pharmacy or uses a registered 503B facility.

Our prescription refill support can help organize the next steps, although no service can override dispensing requirements or guarantee stock.

Ask the prescriber for a dated plan

The plan should identify:

  • The next product or treatment path
  • The prescribed dose
  • The next injection date
  • Whether retitration is needed
  • What to do about missed doses
  • Which symptoms require prompt care

How to switch without guessing the dose

There is no universal dose conversion among compounded vials, approved pens, semaglutide brands, and other GLP-1 drugs.

Syringe units measure volume, not milligrams. The same syringe marking can represent a different drug amount when the concentration changes.

Four details that can change in a switch

A switch may alter:

  • The drug and approved use
  • Dose and concentration
  • Vial, syringe, or pen
  • Injection date and titration schedule

Old syringe units should never be copied directly to a new vial or pen without written instructions.

When a treatment gap may change the plan

A gap in treatment may affect the restart dose or titration schedule. The prescriber should consider the previous dose, side effects, treatment goal, and time since the last injection.

Our guide on how to stop taking semaglutide safely explains issues to discuss with a clinician.

Symptoms that need prompt care

Seek prompt medical advice for severe or persistent abdominal pain, repeated vomiting, dehydration, or signs of an allergic reaction. Emergency symptoms require emergency care rather than a routine refill request.

Options when approved semaglutide costs too much

The shortage can end while treatment remains unaffordable. Depending on clinical needs, a prescriber may discuss another approved product, a non-GLP-1 medication, or a monitored pause.

At Temi, we can support prescriber review and transition planning. We cannot guarantee a prescription, insurance decision, price, or dispensing date.

Compare the full monthly cost

Include the prescription, appointments, laboratory work, supplies, shipping, and follow-up care. Check formulary rules, deductibles, prior authorization requirements, and current manufacturer program terms.

Review safety before a new prescription

Before switching, the clinician should review other medications, relevant medical history, pregnancy plans, contraindications, and product-specific warnings. Treatment decisions require individual clinical review.

FAQ

Is compounded semaglutide now banned?

Not in every circumstance. The broad shortage-based route for routine copies ended, but limited patient-specific compounding may remain possible when applicable requirements are met.

Why can I not find my dose if the FDA says the shortage ended?

The FDA finding reflects national supply and demand, not each pharmacy’s stock. Local demand, shipment timing, wholesaler limits, and stocking policies can still affect availability.

Not automatically. A different concentration or added ingredient does not by itself establish a significant clinical difference or satisfy every legal requirement.

Can I use my old dose with a new vial or pen?

Do not assume so. The product, concentration, device, and titration schedule may differ. Get written dosing and timing instructions from the prescriber.

Should I buy extra compounded semaglutide before a deadline?

We do not recommend stockpiling. Storage requirements, beyond-use dates, dosing accuracy, sourcing, and dispensing policies can all affect whether the medication remains suitable.

Get a dated refill and transition plan

If a refill has been denied or delayed, gather the label, concentration, last dose, remaining supply, and next injection date. Then use Temi’s prescription refill support to request a prescriber review and a dated transition plan.

Editorial Standards

This article has not been reviewed by a licensed physician. We cite peer-reviewed studies, academic research institutions, and medical associations. Our sources are listed at the end of each article.

If you notice an error or have a concern about our content, please email supportusetemi.com.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.

Felt Temigami re-enacting famous revolutions, from crossing the Delaware to raising a pill-bottle flag.

The revolution will be emailed.

Once a week, roughly. We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy

Temi

Start online, and a licensed physician reviews your request

See if you qualify

A licensed physician reviews every request. Nothing on this page is a prescription.